Singapore, April 19 -- The Health Sciences Authority received information related to the study titled 'TulmiSTAR-01: A two-part, Phase I dose escalation and expansion followed by a randomized, open-la... Read More
Singapore, April 19 -- The Health Sciences Authority received information related to the study titled 'A Master Protocol of an Open-Label, Multi-Drug, Multi-Centre, Phase II Study to Evaluate the Safe... Read More
Singapore, April 19 -- The Health Sciences Authority received information related to the study titled 'Role of glucagon-like peptide 1 receptor Agonist (GLP1 RA) Dulaglutide on cerebral hemodynamics I... Read More
Singapore, April 19 -- The Health Sciences Authority received information related to the study titled 'A randomized, placebo-controlled, participant- and investigator-blinded study to evaluate the eff... Read More
Singapore, April 19 -- The Health Sciences Authority received information related to the study titled 'A Phase 2/3 Randomized Study to Evaluate the Safety, Efficacy, and Optimal Dose of Telisotuzumab ... Read More
Singapore, April 19 -- The Health Sciences Authority received information related to the study titled 'A Study to Evaluate the Effect of Fasting Duration and Temporary Withholding of Tirzepatide on Re... Read More
Singapore, April 19 -- The Health Sciences Authority received information related to the study titled 'A Phase 1/2 Open-Label, Umbrella Platform Design Study of Investigational Agents in Combination W... Read More
नई दिल्ली, अप्रैल 19 -- स्वीडन की टेलीकॉम उपकरण बनाने वाली कंपनी एरिक्सन (Ericsson) के लिए भारत का बाजार तेजी से अहम होता जा रहा है। कंपनी के ताजा नतीजों के मुताबिक, जनवरी-मार्च 2026 तिमाही में इंडिया... Read More
औरैया, अप्रैल 19 -- औरैया, संवाददाता। तिलक नगर स्थित भूतेश्वर मंदिर से रविवार को भगवान परशुराम की भव्य शोभा यात्रा धूमधाम और भक्तिभाव के साथ निकाली गई। शोभा यात्रा में बैंड-बाजों की धुन पर श्रद्धालु ज... Read More
Singapore, April 19 -- The Health Sciences Authority received information related to the study titled 'A Global Multicenter, Open Label, Randomized Phase 3 Registrational Study of Olverembatinib Combi... Read More